Sanofi

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Jochen Beninga

Gary J Nabel

Peter D Kwong

Joerg Thomas Regula

John R Mascola

Zhi-Yong Yang

Huawei Qiu

Tongqing Zhou

Ercole Rao

Christian Beil

Christian Lange

Edward Seung

Carsten Corvey

Jochen Kruip

Mark Connors

Béatrice Cameron

Young Do Kwon

Lan Wu

Wulf Dirk Leuschner

Ling Xu

Ronnie Rong Wei

Cendrine Lemoine

Tarik Dabdoubi

Catherine Prades

Jinghe Huang

Joerg Birkenfeld

Zhen Xing

Chantal Carrez

Katja Kroll

Wulf-Dirk Leuschner

Peter Wonerow

Marion Schneider

Mangaiarkarasi Asokan

Amarendra Pegu

Richard A Koup

Ronnie Wei

Jana Albrecht

Cédric Barriere

Stéphane Guerif

Marie-Cécile Wetzel

Nicole A Doria-rose

Provided herein are trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and wherein and a second pair of polypeptides possess a single variable domain forming a single antigen binding site. In some embodiments, the binding proteins comprise a binding site that binds a CD28 polypeptide, a binding site that binds a CD3 polypeptide, and a binding site that binds a third polypeptide, such as a tumor target protein. In some embodiments, the binding proteins comprise four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins. The disclosure also relates to methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.

Trispecific binding proteins, methods, and uses thereof

The disclosure provides trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation and wherein a second pair of polypeptides forming the binding protein possess a single variable domain. The disclosure also provides methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.

Trispecific and/or trivalent binding proteins

Provided herein are bivalent, bispecific binding proteins that specifically bind to two different HIV-1 Env protein epitopes.

Bivalent, bispecific binding proteins for prevention or treatment of HIV infection

The present invention concerns antibody-like binding protein specifically binding to CD3 and binding specifically to at least one further antigen, for example CD123. The present invention also concerns antibody-like binding protein specifically binding to CD123 and binding specifically to at least one further antigen. The invention further concerns anti-CD3 antibodies and anti-CD123 antibodies. The invention also relates to pharmaceutical compositions comprising the antibody-like binding protein, anti-CD3 antibodies or anti-CD123 antibodies of the invention, and their use to treat cancer. The invention further relates to isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibody-like binding protein, anti-CD3 or anti-CD123 antibody and the use of said anti-CD123 antibody as a diagnostic tool.

Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123

Growing community of inventors

Frankfurt am Main, Germany

Jochen Beninga